Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2021 | SeQure DX | Series A | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 9/2018 | Epic Sciences | Series E | 0 |
| 1/2021 | Encodia | Series C | 75M |
| 7/2021 | Wugen | Series B | 0 |
| 9/2022 | Novome | Series B | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 10/2021 | Immunai | Series B | 215M |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 8/2021 | Humacyte | PIPE | 175M |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 5/2021 | Inari | Series D | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 6/2021 | TRex Bio | Series A | 59M |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 9/2021 | Kytopen | Series A | 0 |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 4/2023 | Function Oncology | Series A | 28M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 9/2020 | Korro Bio | Series A | 0 |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 12/2018 | Kallyope | Series B | 21M |
| 8/2018 | Inari | Series B | 40M |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 3/2019 | Gencove | Seed Round | 3M |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 7/2021 | Deep Genomics | Series C | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 3/2017 | EGenesis | Series A | 0 |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 12/2022 | SonoThera | Series A | 0 |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 10/2017 | Visterra | Series C | 0 |
| 6/2018 | StrideBio | Series A | 15.7M |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 3/2022 | Creyon Bio | Series A | 0 |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 10/2017 | Cydan | Venture Round | 34M |
| 7/2021 | IgGenix | Series A | 0 |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 9/2018 | OncoResponse | Series B | 40M |
| 6/2020 | Element Biosciences | Series B | 30M |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 1/2017 | Halio | Series C | 65M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 11/2019 | Genetron Health | Series D | 71M |
| 4/2018 | QurAlis | Seed Round | - |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 5/2021 | Marvin | Seed Round | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 11/2019 | miRecule | Seed Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 5/2021 | miRecule | Venture Round | 0 |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 10/2021 | DNA Script | Series C | 0 |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 11/2018 | Ribometrix | Series A | 30M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 6/2018 | Cibus | Series C | 70M |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 4/2019 | Insitro | Series A | 100M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 9/2021 | Asher Bio | Series B | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 3/2019 | Imara | Series B | 0 |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 7/2018 | ORIG3N | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2020 | Dren Bio | Series A | 0 |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 3/2021 | StrideBio | Series B | 0 |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 1/2023 | Ensoma | Series B | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 3/2022 | TRex Bio | Series A | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2018 | TCR2 | Series B | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 1/2022 | Korro Bio | Series B | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 12/2022 | Dantari | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2018 | Benson Hill | Series C | 65M |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 11/2022 | Rezo | Series A | 0 |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 2/2018 | Kallyope | Series B | 66M |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 6/2022 | Dren Bio | Series B | 0 |
| 1/2022 | Avalo | Convertible Note | 750k |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
